The anthraquinone derivative KA‐4s reduces energy metabolism and enhances the sensitivity of ovarian cancer cells to cisplatin
Molecular Carcinogenesis · 2024
DOI: 10.1002/mc.23795 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2024. Verfasst von Yingdan Zhao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Guangxi Medical University Cancer Hospital, Guangxi Medical University, Nanning, China. Hauptthemen laut MEDLINE: Cisplatin, Ovarian Neoplasms, Anthraquinones, Energy Metabolism. Die Arbeit nennt 32 Literaturangaben.
Abstract (Originalsprache)
Ovarian cancer is the leading cause of death from female gynecological cancers. Cisplatin (DDP) is a first‐line drug for ovarian cancer treatment. Due to DDP resistance, there is an urgent need for novel therapeutic drugs with improved antitumor activity. AMPK‐mediated metabolic regulatory pathways are related to tumor drug resistance. Our study aimed to determine the relationship between reversing DDP resistance with the anthraquinone derivative KA‐4s and regulating AMPK energy metabolism in ovarian cancer. The results showed that KA‐4s inhibited the proliferation of ovarian cancer cells. The combination of KA‐4s with DDP effectively promoted drug‐resistant ovarian cancer cell apoptosis and inhibited cell migration and invasion. Moreover, KA‐4s decreased the intracellular ATP level and increased the calcium ion level, leading to AMPK phosphorylation. Further studies suggested that the AMPK signaling pathway may be involved in the mechanism through which KA‐4s reduce drug resistance. KA‐4s inhibited mitochondrial respiration and glycolysis; downregulated the glucose metabolism‐related proteins GLUT1 and GLUT4; the lipid metabolism‐related proteins SREBP1 and SCD1; and the drug resistance‐related proteins P‐gp, MRP1, and LRP. The inhibitory effect of KA‐4s on GLUT1 was confirmed by the application of the GLUT1 inhibitor BAY‐876. KA‐4s combined with DDP significantly increased the expression of p‐AMPK and reduced the expression of P‐gp. In a xenograft model of ovarian cancer, treatment with KA‐4s combined with DDP reduced energy metabolism and drug resistance, inducing tumor apoptosis. Consequently, KA‐4s might be evaluated as a new agent for enhancing the chemotherapeutic efficacy of treatment for ovarian cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangxi Medical University Cancer Hospital, Guangxi Medical University, Nanning, China.
- Life Sciences Institute, Guangxi Medical University, Nanning, China.
- Global Regulatory Affairs and Compliance Department, Shanghai Wotai Biotechnology Co., Ltd, Kunming, China.
- College of Pharmacy, Guangxi Medical University, Nanning, China.
Zitieren
APA
Zhao, Y., Li, X., Xu, S., Yang, Y., Chen, Q., Li, J., Tian, W., Zhang, Q., Hou, H., & Li, D. (2024). The anthraquinone derivative KA‐4s reduces energy metabolism and enhances the sensitivity of ovarian cancer cells to cisplatin. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23795
Vancouver
Zhao Y, Li X, Xu S, Yang Y, Chen Q, Li J, et al. The anthraquinone derivative KA‐4s reduces energy metabolism and enhances the sensitivity of ovarian cancer cells to cisplatin. Molecular Carcinogenesis. 2024. doi:10.1002/mc.23795
BibTeX
@article{Zhao2024,
author = {Zhao, Yingdan and Li, Xinxiao and Xu, Shumei and Yang, Yingying and Chen, Qiangjian and Li, Junying and Tian, Wei and Zhang, Qiuping and Hou, Huaxin and Li, Danrong},
title = {The anthraquinone derivative KA‐4s reduces energy metabolism and enhances the sensitivity of ovarian cancer cells to cisplatin},
journal = {Molecular Carcinogenesis},
year = {2024},
doi = {10.1002/mc.23795}
}
EUVIMED